Eli Lilly’s stock soars 600% in five years—can the rally last?
Eli Lilly’s stock has surged in recent years, climbing nearly 200% over three years and over 600% in five. The company’s strong performance comes largely from its weight loss drugs, Mounjaro and Zepbound, which now make up more than half of its sales. Yet, with shares trading near record highs, some analysts question whether the growth is already reflected in the price.
The pharmaceutical giant has seen remarkable gains, with its stock rising 43% in the past year alone. This far outpaces the S&P 500’s 12% increase and the 14% average for drug stocks. Much of this success stems from Mounjaro and Zepbound, which reported year-over-year sales growth of 94% and over 900% respectively in Q3 2025.
Eli Lilly’s rapid growth has made it a standout in the pharmaceutical sector, but its high valuation and dependence on a small number of drugs introduce uncertainty. While growth investors may still see potential, value-focused buyers could find the current price too steep. Future performance will likely hinge on whether the company can maintain its momentum amid rising competition.
